全文获取类型
收费全文 | 37417篇 |
免费 | 2697篇 |
国内免费 | 1111篇 |
专业分类
耳鼻咽喉 | 121篇 |
儿科学 | 804篇 |
妇产科学 | 865篇 |
基础医学 | 5572篇 |
口腔科学 | 300篇 |
临床医学 | 3916篇 |
内科学 | 5141篇 |
皮肤病学 | 478篇 |
神经病学 | 724篇 |
特种医学 | 636篇 |
外国民族医学 | 11篇 |
外科学 | 8552篇 |
综合类 | 5217篇 |
现状与发展 | 8篇 |
预防医学 | 2511篇 |
眼科学 | 181篇 |
药学 | 2322篇 |
19篇 | |
中国医学 | 612篇 |
肿瘤学 | 3235篇 |
出版年
2024年 | 90篇 |
2023年 | 547篇 |
2022年 | 887篇 |
2021年 | 1327篇 |
2020年 | 1259篇 |
2019年 | 1159篇 |
2018年 | 1222篇 |
2017年 | 1206篇 |
2016年 | 1163篇 |
2015年 | 1213篇 |
2014年 | 2037篇 |
2013年 | 2217篇 |
2012年 | 1693篇 |
2011年 | 2169篇 |
2010年 | 1851篇 |
2009年 | 1777篇 |
2008年 | 1775篇 |
2007年 | 1875篇 |
2006年 | 1743篇 |
2005年 | 1591篇 |
2004年 | 1401篇 |
2003年 | 1182篇 |
2002年 | 1150篇 |
2001年 | 996篇 |
2000年 | 828篇 |
1999年 | 769篇 |
1998年 | 682篇 |
1997年 | 634篇 |
1996年 | 558篇 |
1995年 | 430篇 |
1994年 | 462篇 |
1993年 | 418篇 |
1992年 | 330篇 |
1991年 | 290篇 |
1990年 | 338篇 |
1989年 | 229篇 |
1988年 | 223篇 |
1987年 | 178篇 |
1986年 | 157篇 |
1985年 | 250篇 |
1984年 | 185篇 |
1983年 | 134篇 |
1982年 | 131篇 |
1981年 | 100篇 |
1980年 | 86篇 |
1979年 | 76篇 |
1978年 | 63篇 |
1977年 | 43篇 |
1976年 | 39篇 |
1975年 | 17篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
21.
胃癌和胃癌前病变Cx43、PCNA的表达及意义 总被引:3,自引:1,他引:2
目的 通过观察间隙连接蛋白 Cx4 3和增殖细胞核抗原 (PCNA )在正常胃粘膜、胃癌前病变和胃癌中的表达和分布情况 ,探讨 Cx基因表达与胃癌发生的关系。 方法 运用 SP免疫组织化学方法检测 Cx4 3、PCNA在 70例原发性胃癌 ,6 2例中、重度不典型增生和 16例正常胃粘膜中表达规律。 结果 Cx4 3在正常胃粘膜 ,中、重度不典型增生和胃癌中表达的阳性率分别为 10 0 % ,83.9%和 17.1% ,三者比较差异有显著性 (P<0 .0 5 )。 Cx4 3表达与胃癌的分化程度相关 (P<0 .0 1)。胃癌前病变、胃癌组中的 PCNA较正常胃粘膜组增高 (P<0 .0 1)。 Cx4 3表达与 PCNA呈负相关 (P<0 .0 1)。 结论 Cx4 3表达降低在胃癌发生发展中起重要作用 ,Cx4 3可做为胃癌早期诊断的指标 相似文献
22.
23.
目的 评价总前列腺特异性抗原 (tPSA)、游离前列腺特异性抗原 (fPSA)及百分率 (f/tPSA % )检测前列腺癌 (PCa)的相关性及临床价值。方法 用酶免法测定 35例PCa及 73例良性前列腺增生 (BPH)患者血清tPSA水平 ,4tPSA <10ng/ml患者另测其fPSA ,计算f/tPSA(% )。 结果 血清tPSA <4、4~ 10、>10ng/ml者发现PCa的比例组间相比均有统计学意义。 4~ 10ng/ml组 ,PCa和BPH者f/tPSA(% )分别是 9.1± 4.8、16 .4± 6 .1,差别有显著意义 (P <0 .0 1)。结论 tPSA仍是PCa筛查的有效瘤标 ,tPSA低水平时 ,f/tPSA(% )检测PCa则更为灵敏精确。 相似文献
24.
25.
26.
Advanced age has been associated with a wide range of defects in both the innate and adaptive immune systems including diminished specific antibody responses that increase the risk of invasive pneumococcal disease (IPD) and limit the effectiveness of vaccines. However, the elderly are a heterogeneous group and measures of overall frailty may be a better indicator of disease susceptibility (or vaccine response) than chronological age alone. 相似文献
27.
The aim was to determine whether the immunogenicity of an investigational hepatitis B vaccine (spHB) is at least as high as that of a licensed control vaccine, Engerix B®, and to evaluate its safety before inclusion in new pediatric combination vaccines. Two randomized, controlled, blind-observer, Phase 3 trials were performed: one in Argentina (344 participants aged 10–15 years, 10 μg HBsAg/dose) and one in Uruguay (344 participants aged 16–45 years, 20 μg HBsAg/dose). Both vaccines were given in a 0, 1, 6 month schedule to all participants with a baseline anti-Hep B antibody titer <0.6 mIU/mL. Antibody titers were measured pre-dose 1, 1 month after dose 2, pre-dose 3, and 1 month after dose 3. Statistical non-inferiority analyses were performed on seroprotection rates (SP) post-dose 3 (% with anti-Hep B titers ≥10 mIU/mL; delta non-inferiority limit of −10%). In both studies, SP for the spHB vaccine was 100% and the spHB vaccine was non-inferior in terms of SP to the licensed control vaccine. GMTs post-dose 3 were approximately 1.8- and 4.1-fold higher for spHB in the 10–15 year and 16–45 year age groups, respectively. Reactogenicity was low for each vaccine, after each dose. This highly immunogenic hepatitis B candidate vaccine was selected for further investigation as a component of new pediatric combination vaccines. 相似文献
28.
Bacterial ghosts (BGs) are empty bacterial envelopes of Gram-negative bacteria produced by controlled expression of cloned gene E, forming a lysis tunnel structure within the envelope of the living bacteria. BGs are devoid of cytoplasmic content and possess all bacterial bio-adhesive surface properties in their original state while not posing any infectious threat. BGs are ideally suited as an advanced drug delivery system (ADDS) for toxic substances in tumor therapy. The inner space of BGs can be loaded with either single components or combinations of peptides, drugs or DNA which provides an opportunity to design new types of (polyvalent) drug delivery vehicles. Uptake of BGs loaded with Doxorubicin (Dox) by CaCo2 cells led to effective Dox release from endo-lysosomal compartments and accumulation in the nucleus. Viability and proliferative capacity of the cells were significantly decreased (2–3 orders of magnitude) after internalization of Dox loaded BGs as compared to cells incubated with free Dox. The same effect was observed with leukemia cells. Melanoma cells also revealed a high capability to internalize BGs. These results indicate that BGs are able to target a range of types of cancer. BGs have also been investigated as DNA delivery vectors. Studies show DNA loaded BGs are efficiently phagocytosed and internalized by both professional APCs and tumor cells with up to 82% of cells expressing the plasmid-encoded reporter gene. Our studies with BGs as an ADDS system contribute (i) to optimize drug delivery for the treatment of cancer; (ii) define specific conditions for selection and preparation of BG formulations; (iii) and provide a background for the clinical application of BGs in cancer therapy. 相似文献
29.
H. S. Pollinger M. D. Stegall J. M. Gloor S. B. Moore S. R. Degoey N. A. Ploeger W. D. Park H. S. Pollinger M. D. Stegall J. M. Gloor S. B. Moore S. R. Degoey N. A. Ploeger W. D. Park 《American journal of transplantation》2007,7(4):857-863
The immunologic risk associated with donor-specific antibodies (DSA) against Class II human leukocyte antigens (HLA) in kidney transplant (KTx) recipients is unclear. The aim of this study was to determine the outcome of KTx when DSA was detected only against HLA Class II. To isolate the impact of anti-Class II DSA, we retrospectively analyzed 12 KTx recipients who at baseline had a positive B-cell flow cytometric crossmatch (FXM) and a negative T-cell FXM. Using alloantibody specification analysis, 58.3% (7/12) had DSA against donor Class II and 41.7% had no demonstrable DSA. Biopsy-proven AMR occurred in 57% (4/7) in the Class II(+) group and 0% in the Class II(-) group (p > 0.05). Peritubular capillaries stained positive for C4d in 86% (6/7) of the Class II(+) patients and in 40% (2/5) of the Class II(-) patients (p > 0.05). One patient in the Class II(+) group lost their graft at 3 months to accelerated transplant glomerulopathy, while all other grafts were functioning 3-37 months posttransplant despite the persistence of anti-Class II DSA. We conclude that KTx recipients with clearly defined anti-Class II DSA are at risk for humoral rejection suggesting that desensitization and/or close posttransplant monitoring may be needed to prevent AMR. 相似文献
30.
J.-M. Halimi M. Buchler A. Al-Najjar I. Laouad Valérie Chatelet J.-F. Marlière H. Nivet Y. Lebranchu 《American journal of transplantation》2007,7(3):618-625
BACKGROUND: Microalbuminuria and macroalbuminuria constitute risk factors for ESRD and death in non-transplanted populations. Whether microalbuminuria (especially in non-proteinuric patients) and macroalbuminuria constitute risk factors for graft loss and death is presently unknown in renal transplantation. METHODS: We retrospectively assessed the association between urinary albumin excretion (UAE) and ESRD and death in renal transplantation. RESULTS: UAE was measured in 616 (397 proteinuric; 219 non-proteinuric patients) renal transplant recipients. They were grafted for 62 months (range: 6-192). During the 40 months (3.7-99) thereafter, 31 patients underwent dialysis and 32 died. Microalbuminuria (vs. normoalbuminuria) and macroalbuminuria (vs. microalbuminuria) were powerful risk factors for graft loss [OR: 14.25 (2.88-52.3) and 16.41 (7.46-36.0), respectively, both p < 0.0001], even after adjustments on renal function and diabetes. Among the 219 non-proteinuric patients, microalbuminuria (vs. normoalbuminuria) was a significant risk factor for graft loss [OR: 23.09 (1.93-276.4), p = 0.0132]. Both microalbuminuria (vs. normoalbuminuria) [OR: 5.55 (2.43-12.66), p < 0.0001] and macroalbuminuria (vs. microalbuminuria) [OR: 4.12 (1.65-10.29), p = 0.0024] were predictive of death. CONCLUSIONS: Microalbuminuria and macroalbuminuria are powerful independent predictors of ESRD and death. Microalbuminuria is a risk factor for graft loss even in non-proteinuric patients. UAE provides additional information on renal and patient prognosis as compared to proteinuria and renal function. 相似文献